153435-84-8

Basic information

• Product Name: 3-BROMOBENZYLMETHYLSULFONE
• Synonyms: 3-BROMOBENZYLMETHYLSULFONE
• CAS NO: 153435-84-8
• Molecular Formula: C₈H₉BrO₂S
• Molecular Weight: 249.12
• Mol File: 153435-84-8.mol

Chemical Properties

• Melting Point: 95-96°C
• Boiling Point: 409.0±28.0 °C(Predicted)
• Appearance: /
• Density: 1.562±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 3-BROMOBENZYLMETHYLSULFONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMOBENZYLMETHYLSULFONE(153435-84-8)
• EPA Substance Registry System: 3-BROMOBENZYLMETHYLSULFONE(153435-84-8)

Safety Data

• Hazardous Substances Data: 153435-84-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromobenzylmethylsulfone is used as a reagent in organic synthesis for the development of new pharmaceutical compounds. Its unique structure and reactivity make it a valuable component in the synthesis of various drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromobenzylmethylsulfone is employed as a reagent in the synthesis of agrochemicals, such as pesticides and herbicides. Its properties allow for the creation of effective compounds that can protect crops and enhance agricultural productivity.
Used as a Precursor in Chemical Production:
3-Bromobenzylmethylsulfone also serves as a precursor in the production of other chemical compounds. Its versatility in organic synthesis reactions enables the creation of a wide range of chemicals for various applications, further expanding its utility in the chemical industry.

Upstream product

• 823-78-9 meta-bromobenzyl bromide 
• 20277-69-4 sodium methansulfinate 
• 1285553-12-9 N'-(3-bromobenzylidene)methanesulfonohydrazide 
• 62247-78-3 1-bromo-3-(dibromomethyl)benzene 

Downstream Products

• 1402601-85-7 3-(2-fluoro-4-((3-((methylsulfonyl)methyl)phenyl)ethynyl)phenyl)propanoic acid 
• 1402602-01-0 methyl 3-(2-fluoro-4-((3-((methylsulfonyl)methyl)phenyl)ethynyl)phenyl)propanoate 
• 1035388-07-8 4-(4-(3-(methylsulfonylmethyl)phenyl)-1H-benzoimidazol-2-yl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amine 

Relevant articles and documents

Discovery of TUG-770: A highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes

Free fatty acid receptor 1 (FFA1 or GPR40) enhances glucose-stimulated insulin secretion from pancreatic β-cells and currently attracts high interest as a new target for the treatment of type 2 diabetes. We here report the discovery of a highly potent FFA1 agonist with favorable physicochemical and pharmacokinetic properties. The compound efficiently normalizes glucose tolerance in diet-induced obese mice, an effect that is fully sustained after 29 days of chronic dosing.

ORTHO-FLUORO SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES

There is provided novel fluoro-substituted compounds capable of modulating the G- protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type II diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.

Synthesis of sulfones by iron-catalyzed decomposition of sulfonylhydrazones

The Fe-catalyzed decomposition of sulfonylhydrazones gives rise to sulfones. The reaction is quite general and allows the preparation of sulfones from a variety of aryl, alkyl, and α,β-unsaturated aldehydes and ketones. Crossover experiments reveal that the reaction is an intermolecular process, which may proceed by nucleophilic attack of the sulfinate anion on an iron carbene complex. Carbonyl compounds can be easily transformed into sulfones by Fe-catalyzed decomposition of the corresponding sulfonylhydrazones. The process most likely proceeds through an iron carbene complex and opens the door for the design of othernovel Fe-catalyzed reductive couplings. Copyright

TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE

Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.

COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE

Compounds of formula (I), a pharmaceutically acceptable salt, solvate or prodrug thereof are disclosed: wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1 4alkylamino; R2 and R3, which may be the same or different, are

Novel synthesis of sulfones from α,α-dibromomethyl aromatics

A novel, high yielding preparation of sulfones from α,α-dibromomethyl aromatics through reaction with a sulfinate salt is reported.

Azetidine derivatives, their preparation and medicaments containing them

The invention concerns compounds of formula (1) wherein: R represents a chain (A) or (B); R1 is methyl or ethyl; R2 is either an optionally substituted aromatic or an optionally substituted heteroaromatic ring; R3 and R4, identical or different, are either an optionally substituted aromatic or an optionally substituted heteroaromatic ring; R′ represents a hydrogen atom or a —CO—alk radical, their optical isomers, their salts, their preparation and medicines containing them.